Discovery of Etelcalcetide for the Treatment of Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease

Call for Papers for a Virtual Special Issue on GPCR Signaling

“…So far, one peptide-based allosteric modulator, etelcalcetide (Parsabiv), has been approved for clinical use against secondary hyperparathyroidism in patients with chronic kidney disease. 8 Other peptide-based allosteric modulators have been discovered through screening efforts or by the mimicry of endogenous peptides or protein domains. 9 The above reflects that there is a scientific playground available to further exploit GPCRs as allosteric microprocessors.…”

“…At the time of this writing, more than 300 entities are in clinical development, with this number set to double in the near future. So far, one peptide-based allosteric modulator, etelcalcetide (Parsabiv), has been approved for clinical use against secondary hyperparathyroidism in patients with chronic kidney disease . Other peptide-based allosteric modulators have been discovered through screening efforts or by the mimicry of endogenous peptides or protein domains .…”